Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates : Episode 8
Opinion
Video
MARIPOSA Study Insights
Author(s):
Benjamin Levy, MD, initiates a discussion on the rationale behind using amivantamab and lazertinib as a first-line treatment for EGFR-mutant non-small cell lung cancer and reviews the recently presented efficacy and safety data from the MARIPOSA trial.
EP: 1.Treatment Strategies for NSCLC with Non-Actionable Mutations
EP: 2.Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02
EP: 3.Exploring the TROPION-Lung04 Study
EP: 4.Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC
EP: 5.Navigating Between ADCs in NSCLC
EP: 6.Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2
EP: 7.Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC
Now Viewing
EP: 8.MARIPOSA Study Insights
EP: 9.Optimizing Therapy Selection in EGFR Mutant NSCLC
EP: 10.ASCO 2024 Updates: Novel Approaches in NSCLC Therapy
EP: 11.Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC
EP: 12.Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape
EP: 13.Targeting of HER3: Insights from HERTHENA-Lung01
EP: 14.Challenges and Learnings from EVOKE-01
EP: 15.Key ADC Studies at ASCO 2024
EP: 16.Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd
EP: 17.Patient Selection and Sequencing of NSCLC ADCs
- Please comment on the rationale for the use of amivantamab and lazertinib in 1L EGFR-mutant NSCLC and discuss recently presented efficacy and safety data from MARIPOSA. Cho, et al. ESMO 2023. Abstract LBA14
Related Videos
Related Content
%20(2)%201-Recovered-Recovered.jpg?fit=crop&auto=format)
